FDA advisory committee supports approval of Keytruda for high-risk bladder cancer

An FDA advisory committee today voted to support approval of pembrolizumab for the treatment of patients with bacillus Calmette-Guérin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. The final vote of 9-4 by the Oncologic Drug Advisory Committee reflected the

Read the full article here

Related Articles